Conference Coverage
Conference Coverage
KRISTINE: Three-year data help forge path to T-DM1-based deescalation in HER2+ BC
CHICAGO – T-DM1 plus pertuzumab reduced toxicity in patients with HER2-positive stage I-III breast cancer in the KRISTINE study, but led to lower...
Conference Coverage
Antibody targeting ‘do not eat me’ signals is active in AML, MDS
CHICAGO – 5F9 plus azacitidine eradicated leukemia stem cells in responding patients, providing a mechanism for potential long-term durability.
Conference Coverage
Pregnancy deemed safe in BRCA-mutated breast cancer survivors
Pregnancy did not affect disease-free or overall survival, and complications were similar to the general population.
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
Conference Coverage
Nivo/ipi shrinks early NSCLC before surgery
CHICAGO – Among patients who went on to resection, 44% of those who had received neoadjuvant nivolumab and ipilimumab had a major pathological...
Conference Coverage
Nearly two-thirds of gynecologic oncology respondents experienced sexual harassment
CHICAGO – A survey suggests sexual harassment remains rampant in the gynecologic oncology field, with both women and...
Conference Coverage
Inhibitor produces high response rate in relapsed/refractory FL
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...
Conference Coverage
Program meets social needs of 90% of patients
WASHINGTON – More than a quarter of patients screened identified having one or more social need.
Conference Coverage
Survival exceeds 90% in transplant for SCD
FORT LAUDERDALE, FLA. — A pilot study has shown one-year overall survival rates exceeding 90% for bone marrow transplants in adults with severe...
Conference Coverage
Olanzapine improves upon standard antiemetic therapy
CHICAGO – Complete response rates were higher among patients who received olanzapine plus standard therapy.
Conference Coverage
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCL
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...